Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 May 2024 | Story Valentino Ndaba | Photo Supplied
Security Policy 2024
Security Policy ensures a safe haven for learning and growth at the University of the Free State.

Fostering an environment conducive to high-quality learning and teaching is paramount at the University of the Free State (UFS). “This commitment extends beyond academic pursuits to encompass the well-being and safety of every member of our university community,” says Cobus van Jaarsveld, Deputy Director of Threat Detection, Investigations, Compliance, and Liaison at the Department of Protection Services.

The university’s dedication to safety in alignment with Vision 130, our Strategic Plan 2023-2028. Protection Services at UFS adheres to a standard of excellence in all aspects of university life. “We prioritise integrity, accountability, and responsibility, striving to create an environment where the happiness and the well-being of our community are central,” adds Van Jaarsveld.

To uphold these values effectively, UFS has initiated a review of the Security Policy, reflecting a renewed approach to safety and security. This policy aims to enhance the UFS experience by ensuring the safety and security of individuals, property, and information across all campuses, satellite sites, and university premises.

Foundational principles

The Security Policy is built upon several core principles. These include a commitment to excellence, ensuring alignment with institutional goals and national legislation, as well as prioritising safety across UFS locations. Partnerships with stakeholders are emphasised to effectively address security challenges. Additionally, the policy highlights universal access, aiming to make safety measures accessible to all members of the university community, including those with disabilities.

Aim and strategies of the policy

The aim of the Security Policy is multifaceted. It seeks to establish a unified approach to safety and security, engaging all pertinent stakeholders in a coordinated effort. Furthermore, the policy endeavours to bolster infrastructure and equip security personnel with the necessary resources to preemptively identify and address potential threats. It also strives to cultivate a culture of heightened security consciousness and active community participation. Compliance with pertinent legislation, particularly in areas such as firearm control, is prioritised. The execution of all security-related functions is entrusted to Protection Services as outlined within the policy framework.

Protection Services personnel are tasked with:

• Identifying and assessing security risks.
• Issuing early warnings and incident reports.
• Responding to emergencies and investigating incidents.
• Developing and implementing security guidelines and protocols.
• Educating and raising awareness within the university community.

• Supporting off-campus students in emergencies and reporting incidents.

At UFS, safety and security are not just policies; they are foundational elements of the university’s commitment to excellence and community well-being. Through collaboration, vigilance, and a proactive approach, the UFS strives to create an environment where everyone can thrive and contribute to a brighter future.

Contact Protection Services 

Bloemfontein Campus Protection Services: +27 51 401 2911 or +27 51 401 2634
South Campus Protection Services: +27 51 505 1217 
Qwaqwa Campus Protection Services: +27 58 718 5460 or +27 58 718 5175

Click to view documentClick here to download the UFS Security Policy.


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept